Horizon Pharma Sees Mid-2019 BLA For Tepro After Solid Phase III TED Data

Shares in Horizon Pharma PLC soared after the Ireland-based specialty pharma said its lead candidate asset had met primary and secondary endpoints in a confirmatory Phase III trial for treating thyroid eye disease (TED), increasing chances teprotumumab will become the first-ever approved treatment for the condition.

Thyroid eye disease a relatively rare and debilitating autoimmune disease of the tissue around the eye associated with Graves' disease,